8-K filed Sep 11, 2026 at 07:45 ET
Karyopharm Therapeutics has entered into a forbearance agreement with 100% of its term loan lenders, convertible noteholders, and royalty investors, after failing to make a ~$15.8M principal payment due September 10, 2026, and not expecting to pay cash interest due September 30, 2026. The forbearance period runs to October 15, 2026, providing a short window to negotiate a restructuring, raise equity, or pursue strategic alternatives, but the company explicitly states that absent additional funding, it will be unable to continue as a going concern and may seek bankruptcy protection. As consideration, the company will issue $20M of convertible preferred stock (convertible at $1.62/share) to the consenting lenders, adding further dilution risk to common equity holders.